Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda’s Febuxostat Finally Gets U.S. Advisory Panel Review

This article was originally published in PharmAsia News

Executive Summary

Takeda North America's long-delayed investigational gout drug febuxostat, previously the subject of two "approvable" letters, will be reviewed by the U.S. FDA Arthritis Drugs Advisory Committee on Nov. 24

You may also be interested in...

Japanese Takeda Buys Abbott’s Stake In TAP Joint U.S. Venture

Japanese drug maker Takeda will establish Takeda America Holdings after finalizing a deal March 19 to obtain a 100 percent stake in TAP Pharmaceutical Products, its 50/50 joint venture with Abbott

Teijin's Novel Gout Drug To Launch In Europe

SHANGHAI - Teijin Pharma will launch xanthine oxidase inhibitor TMX67, its novel gout drug, in Europe, the company announced Feb. 25.The Tokyo-based company received a positive recommendation Feb. 21 from the European Medicines Agency's Committee for Medicinal Products for Human Use

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts